Gentamicin release from commercially-available gentamicin-loaded PMMA bone cements in a prosthesis-related interfacial gap model and their antibacterial efficacy
Open Access
- 10 November 2010
- journal article
- research article
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 11 (1) , 1-9
Abstract
Around about 1970, a gentamicin-loaded poly (methylmethacrylate) (PMMA) bone cement brand (Refobacin Palacos R) was introduced to control infection in joint arthroplasties. In 2005, this brand was replaced by two gentamicin-loaded follow-up brands, Refobacin Bone Cement R and Palacos R + G. In addition, another gentamicin-loaded cement brand, SmartSet GHV, was introduced in Europe in 2003. In the present study, we investigated differences in gentamicin release and the antibacterial efficacy of the eluent between these four cement brands. 200 μm-wide gaps were made in samples of each cement and filled with buffer in order to measure the gentamicin release. Release kinetics were related to bone cement powder particle characteristics and wettabilities of the cement surfaces. Gaps were also inoculated with bacteria isolated from infected prostheses for 24 h and their survival determined. Gentamicin release and bacterial survival were statistically analysed using the Student's t-test. All three Palacos variants showed equal burst releases but each of the successor Palacos cements showed significantly higher sustained releases. SmartSet GHV showed a significantly higher burst release, while its sustained release was comparable with original Palacos. A gentamicin-sensitive bacterium did not survive in the high gentamicin concentrations in the interfacial gaps, while a gentamicin-resistant strain did, regardless of the type of cement used. Survival was independent of the level of burst release by the bone cement. Although marketed as the original gentamicin-loaded Palacos cement, orthopaedic surgeons should be aware that the successor cements do not appear to have the same release characteristics as the original one. Overall, high gentamicin concentrations were reached inside our prosthesis-related interfacial gap model. These concentrations may be expected to effectively decontaminate the prosthesis-related interfacial gap directly after implantation, provided that these bacteria are sensitive for gentamicin.Keywords
This publication has 19 references indexed in Scilit:
- Generic Tobramycin Elutes From Bone Cement Faster Than Proprietary TobramycinClinical Orthopaedics and Related Research, 2008
- Orthopaedic bone cementThe Journal of Bone and Joint Surgery. British volume, 2008
- In vitro study of the efficacy of acrylic bone cement loaded with supplementary amounts of gentamicin: Effect on mechanical properties, antibiotic release, and biofilm formationActa Orthopaedica, 2007
- Inter- and intra-batch variability in the handling characteristics and viscosity of commonly used antibiotic-loaded bone cementsActa Orthopaedica, 2007
- In vitro comparison of Refobacin-Palacos R with Refobacin Bone Cement and Palacos R + GActa Orthopaedica, 2007
- The effect of mixing on gentamicin release from polymethylmethacrylate bone cementsActa Orthopaedica, 2003
- The release of gentamicin from acrylic bone cements in a simulated prosthesis‐related interfacial gapJournal of Biomedical Materials Research Part B: Applied Biomaterials, 2002
- Effect of antibiotics on the properties of poly(methylmethacrylate)‐based bone cementJournal of Biomedical Materials Research, 2002
- Methods for improving drug release from poly( ethyl)methacrylate bone cementClinical Materials, 1991
- Comparison of New and Existing Spectrophotometric Methods for the Analysis of Tobramycin and Other AminoglycosidesJournal of Pharmaceutical Sciences, 1990